SUPN

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue, with Qelbree and ZURZUVAE driving robust prescription and sales growth. Combined entity targets $2.2B revenue, $888M adjusted EBITDA, $125M synergies, and trades at ~7x synergized EBITDA—suggesting a mispriced, underappreciated value.

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:

ROCKVILLE, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Professional snowboarder, Chloe Kim, is partnering with Supernus Pharmaceuticals as a compensated ambassador to discuss her journey with attention-deficit/hyperactivity disorder (ADHD) and her treatment plan with Qelbree (viloxazine extended-release capsules), a once-daily, non-stimulant medication for patients 6 years and older. Designed for flexible once-a-day routine integration, Qelbree offers 24-hour medication exposure, no evidence of abuse potential, and versatile administration options, including the ability to be sprinkled and taken at any time of day (either morning or night). Through this partnership, Chloe Kim will open up about her own diagnosis to challenge misconceptions about ADHD. By sharing her lived experience, she will encourage others to advocate for their health and initiate collaborative conversations with their doctors about a potential treatment plan.

Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?